Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing - PubMed (original) (raw)

. 2009 Nov 1;18(21):4153-70.

doi: 10.1093/hmg/ddp367. Epub 2009 Aug 4.

Affiliations

Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing

Yipeng Wang et al. Hum Mol Genet. 2009.

Abstract

Aggregation and cleavage are two hallmarks of Tau pathology in Alzheimer disease (AD), and abnormal fragmentation of Tau is thought to contribute to the nucleation of Tau paired helical filaments. Clearance of the abnormally modified protein could occur by the ubiquitin-proteasome and autophagy-lysosomal pathways, the two major routes for protein degradation in cells. There is a debate on which of these pathways contributes to clearance of Tau protein and of the abnormal Tau aggregates formed in AD. Here, we demonstrate in an inducible neuronal cell model of tauopathy that the autophagy-lysosomal system contributes to both Tau fragmentation into pro-aggregating forms and to clearance of Tau aggregates. Inhibition of macroautophagy enhances Tau aggregation and cytotoxicity. The Tau repeat domain can be cleaved near the N terminus by a cytosolic protease to generate the fragment F1. Additional cleavage near the C terminus by the lysosomal protease cathepsin L is required to generate Tau fragments F2 and F3 that are highly amyloidogenic and capable of seeding the aggregation of Tau. We identify in this work that components of a selective form of autophagy, chaperone-mediated autophagy, are involved in the delivery of cytosolic Tau to lysosomes for this limited cleavage. However, F1 does not fully enter the lysosome but remains associated with the lysosomal membrane. Inefficient translocation of the Tau fragments across the lysosomal membrane seems to promote formation of Tau oligomers at the surface of these organelles which may act as precursors of aggregation and interfere with lysosomal functioning.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Effects of NH4Cl and 3-MA on the cleavage, aggregation and cytotoxicity of TauRDΔK in N2a cells. (A) Diagram of TauRD showing cleavage sites and CMA recognition motifs. TauRD is first cleaved after K257 to generate F1, then after V363 to generate F2, and further after I360 to produce F3. The two CMA recognition motifs are 336QVEVK340 and 347KDRVQ351. (B and C) Blot analysis of effects of proteasomal inhibitors (epoxomicin or MG132) (B) or autophagy–lysosomal inhibitors (3-MA or NH4Cl) (C) on cleavage and oligomerization of TauRDΔK. N2a cells overexpressing TauRDΔK were treated with these inhibitors for 5 days. Lanes labeled P (=pellet) denote sarkosyl-insoluble Tau species, S (=supernatant) indicates soluble proteins. Note that NH4Cl but not 3-MA inhibits the cleavage and aggregation of TauRDΔK. (D) ThS staining showing the influence of 3-MA and NH4Cl on Tau aggregation. (E) Quantification of ThS positive cells, which increase ∼5-fold with 3-MA but not with NH4Cl. (F) Effects of NH4Cl and 3-MA on the cytotoxicity of TauRDΔK in N2a cells. The excessive cytotoxicity by Tau was obtained by subtracting cytotoxicity without Tau from cytotoxicity with Tau expression. Note that 3-MA but not NH4Cl aggravates TauRDΔK cytotoxicity.

Figure 2.

Figure 2.

Distribution of Tau constructs in subcellular fractions of N2a cells. N2a cells induced to express TauRDΔK (A and C) or TauRDΔK/2P (B) were treated without or with NH4Cl for 5 days. The cell homogenates (homo) were fractionated into nuclear pellet (NP), containing nuclei and unbroken cells, cytosol (cyto), ER, mitochondria (Mito) and lysosomes (Lyso). To clearly distinguish the F1 band from the intact TauRDΔK band, the same samples but only half of the amount used in (A) were loaded in (C). Note that fragments F2 and F3 were only detected in the lysosomal fraction from N2a cells expressing TauRDΔK, whereas F1 can be detected in the cytosol or ER fractions.

Figure 3.

Figure 3.

Cleavage of Tau constructs by cytosol, lysosomal matrix or cathepsin L and release of lysosomal hydrolase β-hexosaminidase into the cytosol of N2a cells caused by expression of TauRDΔK. (A) TauRDΔK incubated with cytosol fraction from rat liver. Note the appearance of fragment F1 (but not F2 or F3) and oligomeric aggregates (mostly dimers). (B) F1 incubated with cytosol fraction from rat liver. Note that there is no cleavage of F1. (C) F1 incubated with lysosomal matrix fraction from rat liver. Note cleavage of F1 to F2 and F3, as well as generation of oligomers (dimers and trimers). (D) TauRDΔK incubated with cytosol fraction from N2a cells. Note appearance of fragment F1 and oligomers. (E) F1 incubated with lysosomal fraction from N2a cells. Note fragmentation to F2 and F3. (F) Digestion of F1 by cathepsin L. Recombinant F1 (0.1 µg/µl) was incubated with 0.005, 0.06, 0.15, 0.3 or 0.6 U/l cathepsin L in 100 m

m

Na acetate pH 4.5 or 100 m

m

Tris–HCl pH 7.0 for 60 min. Note that fragments F2 and F3 (arrows) are generated by cathepsin L at both pH 7.0 and pH 4.5. (G) Cathepsin L inhibitor reduces generation of F2 and F3. N2a cells expressing TauRDΔK were treated with cathepsin L inhibitor for 3 days at concentrations up to 20 µ

m

. Lanes labeled P (=pellet) denote sarkosyl-insoluble Tau species, S (=supernatant) indicates soluble proteins. (H) Cathepsin L inhibition also inhibits aggregation of Tau. N2a cells expressing TauRDΔK were treated without or with cathepsin L inhibitor for 3 days. ThS staining reveals that inhibition of cathepsin L reduces Tau aggregation as well. (I) Expression of TauRDΔK causes the release of lysosomal hydrolase β-hexosaminidase. N2a cells expressing TauRDΔK were induced to express Tau for 2 days. The cytosolic distribution of β-hexosaminidase is expressed as the percentage of total β-hexosaminidase activity and is shown as mean ± SEM of four different experiments (*P < 0.05).

Figure 4.

Figure 4.

Degradation of Tau by macroautophagy. (A) Blot analysis of effects of inhibiting macroautophagy or lysosomes on Tau clearance. N2a cells expressed TauRDΔK for 6 days, then expression was switched off and cells were treated with or without inhibitors for 2 days. Equal amounts of protein were loaded and checked against actin (A, lower panel). Lanes 1 and 2 show that expression of TauRDΔK generates aggregates in the pellet, fragmentation and a higher molecular weight smear. Stopping expression allows cells to clear most soluble TauRDΔK and aggregates (lane 4), but clearance is impaired if autophagy (3-MA, lane 6) or lysosomal proteases (NH4Cl, lane 8) are inhibited. (B) Quantification of effect of 3-MA and NH4Cl on TauRDΔK280 clearance. (C) Blot analysis of effects of inhibiting proteasome, macroautophagy or lysosomes on hTau40wt or hTau40/KXGE clearance. N2a cells expressed stably hTau40wt or transiently hTau40/KXGE were induced to express Tau for 2 days, then expression was switched off and cells were treated for 1 day with proteasome inhibitors (MG132 or epoxomicin) or 3-MA, or without inhibitor (control). Total Tau and Tau phosphorylated in the repeat domain(KXGS motifs) were determined with antibodies K9JA and 12E8. The level of β-catenin or p62 was measured to check the extent of the inhibition of the proteasomal or macroautophagy system. (D–F) Quantification of the effect of inhibitors on the clearance of hTau40wt (45% increase with 3-MA) (D), phospho-Tau (140% increase) (E) or hTau40/KXGE (240% increase) (F). Values are expressed as relative protein amount compared with the control (mean ± SE of three experiments). Inhibiting the proteasome has a minor effect, whereas inhibiting macroautophagy or lysosomes causes build-up of Tau. Note that Tau phosphorylated at KXGS motifs is a preferred target for macroautophagy (E, column 4).

Figure 5.

Figure 5.

Association of different forms of Tau with isolated lysosomes. (A) Association of the indicated forms of Tau (2 µg) with isolated lysosomes untreated or pre-treated with protease inhibitors (PI). Lanes 2–3, 4–5 show two independent incubations. Input (lane 1): 1/10 of total protein added to lysosomes. Arrows denote intact Tau constructs. Higher molecular weight forms of Tau (olig) can be detected for TauRDΔK and to a lesser extent for F1 (panels 3 and 4,). For hTau40wt and hTau40ΔK, with protease inhibitors, more intact Tau was detected (panels 1 and 2, lanes 3, 5). (B) Quantification of the amount of the indicated forms of Tau associated to lysosomes when incubated under the same conditions. Values are expressed as percentage of the total protein added to the reaction and are mean ± SEM of six different experiments (*P < 0.05). Binding of ribonuclease A (RNase A), under the same conditions is shown as reference. (C) Tau fails to translocate across the lysosomal membrane. Intact rat liver lysosomes treated or not with protease inhibitors were incubated with RNase A and the indicated forms of Tau at 4°C (lanes 3, 4) or 37°C (lanes 5, 6). Increase association at 37°C in the presence of protease inhibitors (indicative of lysosomal uptake) only occurred for RNase A. The similarity of Tau patterns at both temperatures shows that there is no uptake of Tau by CMA. Lanes 1 and 2 show the proteins incubated alone (1/10 of the total protein was added into the gel). (D) Lysosomal Tau is associated to the cytosolic side of the lysosomal membrane as determined by protease protection assay. Lysosomes previously treated with lysosomal protease inhibitors and incubated with the indicated proteins were recovered by centrifugation and resuspended in medium alone (−) or supplemented with trypsin (Try) or proteinase K (Pr K). Note that Tau is on the cytosolic side of the lysosomes because it is completely digested after protease treatment, whereas the fraction of RNase A translocated into lysosomes becomes protected from the exogenous proteases.

Figure 6.

Figure 6.

Competition of the lysosomal association of different forms of Tau by substrates of CMA. (A) Effects of CMA substrate (GAPDH) and CMA non-substrate (ovalbumin) on binding and uptake of Tau by lysosomes. The different forms of Tau proteins (2 µg) and the indicated increasing concentrations of GAPDH or ovalbumin (Oval) were incubated with intact isolated lysosomes previously treated with protease inhibitors. Lane 1 shows 1/10 of the input (i) and insets show the amount of GAPDH associated with the lysosomal membranes. Only association of the F1 fragment and of RNase A (shown here as a positive control) could be competed by increasing concentrations of GAPDH, whereas ovalbumin did not modify lysosomal binding. (B) The percentage of the different Tau proteins and of RNase A bound to the lysosomal membrane in the presence of increasing concentrations of GAPDH was quantified in four experiments similar to the ones shown in (A). Values are mean ± SEM. (C) The maximal inhibition on Tau binding attained by GAPDH was calculated in four experiments similar to the ones shown in (A). Values are mean ± SEM (*P < 0.05). (D and E) Effect of different Tau proteins or GAPDH on the degradation of a pool of CMA substrates by intact lysosomes. Values expressed as % of proteolysis in the absence of Tau (D) or % of maximal inhibition of the degradation of the pool of proteins (E). Values are mean ± SEM of two experiments with triplicate samples. (*P < 0.05 compared with wild-type full-size Tau and §P < 0.05 compared with the inhibitory effect of GAPDH).

Figure 7.

Figure 7.

Effects of mutation of CMA motifs on the interaction of Tau constructs with hsc70 and Tau degradation. (A) Interaction of recombinant TauRDΔK, TauRDΔK CMA mut (CMA recognition motifs mutated), F1 or F1 CMA mut with GST-hsc70 in vitro. Note that there is an interaction between hsc70 and TauRDΔK or F1 in vitro (lanes 5, 7) and the CMA motif mutations reduced this interaction (lanes 6, 8). (B) Interaction of TauRDΔK, TauRDΔK CMA mut, F1 or F1 CMA mut with endogenous hsc70 in N2a cells. There is a strong interaction between hsc70 and TauRDΔK as well as F1 in cells (lanes 5, 7), but reduced interaction between hsc70 and the Tau mutants (lanes 6, 8). (C) Mutation of the CMA motifs blocks TauRDΔK280 cleavage and the generation of F3 from F1. S and P denote supernatant and pellet of sarkosyl extraction, respectively. Note the absence of F3 in the pellet in lanes 4 and 8.

Figure 8.

Figure 8.

Effect of inhibition of CMA components on CMA uptake of Tau proteins. (A) Lysosomal association of TauRDΔK, F1 and its CMA mutants. Increasing concentrations of Tau proteins (as indicated) were incubated with freshly isolated intact lysosomes treated (+) or not (none) with protease inhibitors (PI). i=input (0.2 µg). (B) Quantification of lysosomal binding of the Tau proteins to untreated lysosomes (left) or lysosomes treated with protease inhibitors (right) calculated from three experiments as the ones shown in (A). Values are expressed as percentage of the total protein added and are given as mean ± SEM (*P < 0.05). (C) Effect of antibody blockage of lysosomal CMA components on the association of Tau proteins to lysosomes. The indicated Tau proteins were incubated with freshly isolated intact lysosomes pre-incubated or not with antibodies against LAMP-2A (anti-L2A) and LAMP-2B (anti-L2B). (D) Effects of knockdown of LAMP-2A on TauRDΔK280 fragmentation and aggregation. N2a cells infected with LAMP-2A (L2A) shRNA or control shRNA (CTR) lentivirus for 20 days were induced to express TauRDΔK280 for 3 days. Then sarkosyl extraction was used to separate soluble and insoluble Tau. Right panel, S and P denote sarkosyl supernatant and pellet, respectively. Left panel shows efficiency of knock-down for LAMP-2A. Actin was used as a loading control. Note: LAMP-2A shRNA knocks down the expression of LAMP-2A and reduces the generation of F2 and F3.

Figure 9.

Figure 9.

Model of fragmentation and degradation of TauRDΔK by autophagy–lysosomal system. When TauRDΔK is expressed in N2a cells, it becomes partially cleaved in the cytosol by a thrombin-like activity to generate F1. A fraction of F1 is delivered to lysosomes via CMA components (targeting through hsc70 and binding to the lysosomal membrane via LAMP-2A) where the C-terminal end is cleaved by cathepsin L to generate F2 and F3. These fragments are highly amyloidogenic, nucleate aggregation and induce the co-aggregation of intact TauRDΔK (or full-length Tau) in the cytosol. The aggregates can then be degraded through the macroautophagy pathway.

References

    1. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121–1159. - PubMed
    1. Garcia M.L., Cleveland D.W. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 2001;13:41–48. - PubMed
    1. Mandelkow E., von Bergen M., Biernat J., Mandelkow E.M. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007;17:83–90. - PMC - PubMed
    1. Johnson G.V., Seubert P., Cox T.M., Motter R., Brown J.P., Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J. Neurochem. 1997;68:430–433. - PubMed
    1. Portelius E., Hansson S.F., Tran A.J., Zetterberg H., Grognet P., Vanmechelen E., Hoglund K., Brinkmalm G., Westman-Brinkmalm A., Nordhoff E., et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 2008;7:2114–2120. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources